Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Status:
Terminated
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy of ponatinib and imatinib in patients
with newly diagnosed chronic myeloid leukemia (CML) in the chronic phase.